2. Academic Validation
  3. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates

A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates

  • Sci Transl Med. 2018 Aug 29;10(456):eaar3483. doi: 10.1126/scitranslmed.aar3483.
Huiping Ding 1,  Norikazu Kiguchi 1 2,  Dennis Yasuda 3,  Pankaj R Daga 3,  Willma E Polgar 3,  James J Lu 3,  Paul W Czoty 1,  Shiroh Kishioka 2,  Nurulain T Zaveri 4,  Mei-Chuan Ko 5 6
Affiliations

Affiliations

  • 1 Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
  • 2 Department of Pharmacology, Wakayama Medical University, Wakayama, Japan.
  • 3 Astraea Therapeutics, Mountain View, CA 94043, USA.
  • 4 Astraea Therapeutics, Mountain View, CA 94043, USA. nurulain@astraeatherapeutics.com mko@wakehealth.edu.
  • 5 Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. nurulain@astraeatherapeutics.com mko@wakehealth.edu.
  • 6 W.G. Hefner Veterans Affairs Medical Center, Salisbury, NC 28144, USA.
PMID: 30158150 DOI: 10.1126/scitranslmed.aar3483
Abstract

Misuse of prescription opioids, opioid addiction, and overdose underscore the urgent need for developing addiction-free effective medications for treating severe pain. Mu opioid peptide (MOP) receptor agonists provide very effective pain relief. However, severe side effects limit their use in the clinical setting. Agonists of the nociceptin/orphanin FQ peptide (NOP) receptor have been shown to modulate the antinociceptive and reinforcing effects of MOP agonists. We report the discovery and development of a bifunctional NOP/MOP receptor agonist, AT-121, which has partial agonist activity at both NOP and MOP receptors. AT-121 suppressed oxycodone's reinforcing effects and exerted morphine-like analgesic effects in nonhuman primates. AT-121 treatment did not induce side effects commonly associated with opioids, such as respiratory depression, abuse potential, opioid-induced hyperalgesia, and physical dependence. Our results in nonhuman primates suggest that bifunctional NOP/MOP agonists with the appropriate balance of NOP and MOP agonist activity may provide a dual therapeutic action for safe and effective pain relief and treating prescription opioid abuse.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z